Pneumococcal disease prevention(UTD)

Promotes active immunization against invasive disease caused by S. pneumoniae capsular serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all which are individually conjugated to CRM197 protein.(UTD)

Severe allergic reaction (eg, anaphylaxis) to pneumococcal vaccine, any component of the formulation, or any diphtheria toxoid-containing vaccine.(UTD)

Animal reproduction studies have not shown adverse fetal effects.(UTD)

It is not known if this vaccine is excreted into breast milk.(UTD)

>10%:
Central nervous system: Chills (adults), drowsiness, fatigue (adults), headache (adults), insomnia, irritability (infants and children)
Dermatologic: Skin rash (adults: >10%; children and infants: >1%; including urticaria-like rash)
Gastrointestinal: Decreased appetite
Local: Erythema at injection site, pain at injection site (adults), swelling at injection site, tenderness at injection site
Neuromuscular & skeletal: Arthralgia (adults), decreased range of motion (arm), myalgia (adults)
Miscellaneous: Fever

Immunization: IM: 0.5 mL as a single dose.

Primary immunization: Infants and Children 6 weeks to 15 months: IM: 0.5 mL/dose for a total of 4 doses. The first dose may be given as young as 6 weeks of age, but is typically given at 8 weeks (2 months). The 3 remaining doses are usually given at 4, 6, and 12 to 15 months. The recommended dosing interval is 4 to 8 weeks. The minimum interval between doses in infants <1 year is 1 month. The minimum interval between the third and fourth dose is 8 weeks.